Naproxen/pregabalin conjugate

萘普生/普瑞巴林双效前药偶联物

Report date: 2025/01/10 16:59:13

Base Information

Drug NameNaproxen/pregabalin conjugate
Drug Alias NamePregabalin/Naproxen萘普生+普瑞巴林普瑞巴林/萘普生Pregabalin+NaproxenNaproxen+Pregabalin +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 1 blockersCyclooxygenases inhibitors
TargetsVoltage-gated calcium channel alpha2/delta subunit 1Cyclooxygenases
Therapy Area/IndicationsCancer PainAcute PainPain +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia +[4] 
CombinationsYes NaproxenPregabalin
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesXgene Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeuroGen PharmaXgene Pharmaceutical GroupChangyu Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsCancer PainAcute PainPain +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A